What does erasca do?

Erasca is a clinical-stage precision oncology company driven by a bold mission—to erase cancer. We are on a journey to shut down one of cancer’s most commonly mutated signaling cascades, the RAS/MAPK pathway, which affects approximately 5.5 million lives each year worldwide.

Why is erasca undergoing clinical trials?

Erasca is in the process of initiating a number of clinical trials to evaluate the safety and efficacy of our therapeutic candidates—as monotherapy and in combination regimens—across a range of tumor types.

Does erasca own ERK inhibitors?

Under the terms of the NiKang agreement, Erasca licensed exclusive, worldwide rights to ERAS-601 and all other SHP2 inhibitors developed by NiKang. Under the terms of the Asana agreement, Erasca acquired exclusive, worldwide rights to ERAS-007 and all other ERK inhibitors developed by Asana. Financial terms of both agreements were not disclosed.